OPGN vs. ACON, BGLC, PMD, CNTG, TTOO, DMTK, XGN, ADXS, HCTI, and HILS
Should you be buying OpGen stock or one of its competitors? The main competitors of OpGen include Aclarion (ACON), BioNexus Gene Lab (BGLC), Psychemedics (PMD), Centogene (CNTG), T2 Biosystems (TTOO), DermTech (DMTK), Exagen (XGN), Ayala Pharmaceuticals (ADXS), Healthcare Triangle (HCTI), and Hillstream BioPharma (HILS). These companies are all part of the "medical" sector.
Aclarion (NASDAQ:ACON) and OpGen (NASDAQ:OPGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings, institutional ownership and community ranking.
7.5% of Aclarion shares are owned by institutional investors. Comparatively, 2.7% of OpGen shares are owned by institutional investors. 22.3% of Aclarion shares are owned by company insiders. Comparatively, 1.3% of OpGen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Aclarion and Aclarion both had 1 articles in the media. OpGen's average media sentiment score of 0.84 beat Aclarion's score of 0.00 indicating that Aclarion is being referred to more favorably in the media.
OpGen has a net margin of -852.18% compared to OpGen's net margin of -6,480.47%. Aclarion's return on equity of -316.30% beat OpGen's return on equity.
Aclarion has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500. Comparatively, OpGen has a beta of -0.71, suggesting that its share price is 171% less volatile than the S&P 500.
Aclarion has higher earnings, but lower revenue than OpGen.
OpGen received 300 more outperform votes than Aclarion when rated by MarketBeat users. However, 100.00% of users gave Aclarion an outperform vote while only 56.16% of users gave OpGen an outperform vote.
Summary
Aclarion beats OpGen on 7 of the 12 factors compared between the two stocks.
Get OpGen News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OPGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools